Trial reportPloS one2018
Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative.
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000611 (Women's Health Initiative), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Women's Health Initiative (WHI)
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Hormone replacement therapy in women and risk of carpal tunnel syndrome: a systematic review and metaanalysis.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2023Pooled it
- Genetic evidence elucidates the mediating role of sex hormone-binding globulin in the causal relationship linking insomnia to carpal tunnel syndrome.Human genomics · 2026Article
- Medical Service Utilization for Carpal Tunnel Syndrome in Korea (2010-2017): A Retrospective, Cross-Sectional Study Using a Nationally Representative Sample from the HIRA-National Patient Sample Database.Healthcare (Basel, Switzerland) · 2026Article
- 3D printing visualization combined with home-school-hospital collaboration for clinical pharmacology teaching.Frontiers in pharmacology · 2026Article
- From physiology to psychology: An integrative review of menopausal syndrome.World journal of psychiatry · 2025Review
- Ultrasound Characteristics of Carpal Tunnel Syndrome in the Spanish Population.Journal of clinical ultrasound : JCU · 2025Observational
- Linkage of Clinical Trial Data to Routinely Collected Data Sources: A Scoping Review.JAMA network open · 2025Article
- Article
- Age‑related differences for expression of the nerve‑specific proteins after peripheral nerve injury.Experimental and therapeutic medicine · 2022Article
- Prevalence of Anxiety and Depression Symptoms in People with Carpal Tunnel Syndrome.Revista brasileira de ortopedia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
importanceCarpal tunnel syndrome (CTS) is a common and debilitating condition that commonly affects postmenopausal women.
objectiveTo determine the effect of menopausal hormone therapy (HT) in healthy postmenopausal women on CTS risk.
designWe conducted a secondary analysis of the Women's Health Initiative's (WHI) HT trials linked to Medicare claims data. Separate intention-to-treat analyses were performed for the two trials; the conjugated equine estrogens alone (CEE alone) and the trial of CEE plus medroxyprogesterone acetate (MPA) trial. (ClinicalTrials.gov, NCT number): NCT00000611.
settingTwo randomized, double-blind, placebo-controlled trials conducted at 40 US clinical centers.
participantsThe sample size included in the analysis was 16,053 community-dwelling women aged ≥65 years at study entry or those who later aged into Medicare eligibility, and who were enrolled in Medicare (including Part A and/or Part B coverage).
interventionWomen with hysterectomy were randomized to 0.625 mg/d of conjugated equine estrogens (CEE) or placebo (n = 8376). Women without hysterectomy were randomized to estrogen plus progestin (E+P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate (n = 14203). MAIN OUTCOME(S): The primary outcome was incident CTS and the secondary outcome was therapeutic CTS procedure occurring during the intervention phases of the trials.
resultsA total of 16,053 women were randomized in both trials. During mean follow up of 4.5 ± 2.8 years in the CEE trial (n = 6,833), there were 203 incident CTS cases in the intervention and 262 incident CTS cases in the placebo group (HR, 0.78; 95% CI, 0.65-0.94; P = 0.009). The CEE+MPA trial (n = 9,220) followed participants for a mean of 3.7 ± 2.3 years. There were 173 incident CTS cases in the intervention compared to 203 cases in the placebo group (HR, 0.80, 95% CI, 0.65-0.97; P = 0.027).
conclusionsThese findings suggest a protective effect of menopausal HT on the incidence of CTS among postmenopausal women. A potential therapeutic role for other forms of estrogen therapy in the management of CTS warrants future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.